ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia

  • Post author:
  • Post category:Newsroom

ERYTECH Pharma today announced that it has reached full patient enrollment in the Phase 2b trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of acute myeloid leukemia (AML).

Menu